Navigation Links
Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,,Its New Long Acting Drug For Erectile Dysfunction

icantly (p<0.001) higher compared to 31% in the placebo group. Fifty percent (50%) of the patients in the 150mg group shifted to normal erectile function (EF domain scores >25) after 12 weeks on drug compared to 14% in the placebo group. All three active dose levels were well-tolerated; the most frequently reported adverse events were nasal congestion, flushing and headache and were mostly mild to moderate in intensity. No myalgia, back pain, leg pain or vision disturbances were reported and no serious adverse events related to the drug were reported. Only 4 patients withdrew from the study due to adverse events related to the drug.

Dong-A PharmTech Co., Ltd anticipates that the completion of the phase 2b trial will allow it to proceed with phase 3 clinical trials in the U.S. and Europe.

"We are extremely pleased with the results of this 340 patient phase 2b clinical trial in the U.S. which clearly demonstrated an excellent efficacy and safety profile in erectile dysfunction patients," stated Dong Hyun Park, President and CEO of Dong-A PharmTech. "The completion of this study is a major milestone in the development of udenafil. We plan to aggressively pursue regulatory approval in major markets throughout the world and to replicate in those markets the commercial success already achieved in Korea."

Udenafil was approved by the Korean FDA in November 2005 and launched by Dong-A Pharmaceutical in Korea under the brand name Zydena(R) in late December 2005 as the fourth entrant to the ED market. By the first quarter of 2006, Zydena(R) garnered 21% market share in Korea in terms of tablet volume and effectively expanded the Korean ED market volume by 16% through the introduction of new patients as well as re-entry of former patients. To date, Zydena(R) has maintained its market share, surpassing Levitra(R), and nearly reaching parity with Cialis(R) by sales volume.

Dong-A PharmTech Co., Ltd. has initiated the approval process for udenafil in C
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... , July 10, 2014   LabStyle ... Management Solution, today announced the appointment of Professor ... member of its Board of Directors. ... and business experience to LabStyle as an entrepreneur, ... legal and corporate governance expert. He currently serves ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... strategic transaction processSAN DIEGO, May 7 ADVENTRX ... today announced results from its bioequivalence study of ... have comparable overall safety as Taxotere(R), the reference ... severe toxicities. However, pharmacokinetic equivalence, the primary ...
... is to Enhance Patient Safety and Reduce Health Care ... will join in a pilot program, contributing data on ... the data collected, it will be possible to identify ... patient safety while reducing overall costs to the health ...
Cached Medicine Technology:ADVENTRX Announces Results From ANX-514 Bioequivalence Study 2ADVENTRX Announces Results From ANX-514 Bioequivalence Study 3ADVENTRX Announces Results From ANX-514 Bioequivalence Study 4ADVENTRX Announces Results From ANX-514 Bioequivalence Study 5National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 2National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 3
(Date:7/13/2014)... best treatment and variations in the quality of care ... cancer patients still varies widely between regions within Europe, ... European adults to date, published in The Lancet ... survival for most cancers of the blood has increased ... approval of new targeted drugs in the early 2000s ...
(Date:7/13/2014)... Intraocular Lens (IOL) Market: Global Industry ... 2019 , Intraocular lens (IOL) is inserted in the ... The lenses are inserted inside the eye, after removal ... replaces the focusing power of natural lens. The pseudophakic ... deliver the light focusing function which was originally undertaken ...
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
(Date:7/13/2014)... The North American water storage systems market is estimated to ... 2018, at a CAGR of 21.0%, from 2013 to 2018. ... pace in North America. The U.S. is experiencing high growth ... storage and collection, and the increased spending on modernization and ... healthy rate in Canada, and is rising at a rapid ...
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3
... 11 (HealthDay News) -- Parkinson,s disease patients who receive care ... break a hip or need nursing-home placement than those treated ... American researchers looked at the medical records of all ... Between that time and 2005, 68 percent of the patients ...
... drugs as a first-line treatment for people with tuberculosis (TB) ... not been well understood. Now, researchers have discovered a key ... TB therapy. The finding potentially paves the way for the ... an infected individual even more rapidly. The study was supported ...
... THURSDAY, Aug. 11 (HealthDay News) -- What do a ... A lot more than you might expect, new research ... aquatic reptile with its embryo offers the first evidence ... that they may have had a social structure similar ...
... August 11, 2011) According to a study ... the American Society of Hematology (ASH), researchers have ... that releases stem cells from the bone marrow into the ... risk for later development of abnormalities involving loss or gains ...
... , THURSDAY, Aug. 11 (HealthDay News) -- American women ... those born in 1910 or 1960, according to researchers who analyzed ... 1935 had an average of three children per woman, compared with ... for those born in 1960, their study found. Of the ...
... 11 (HealthDay News) -- Like humans, chimpanzees are born ... to track the development of three chimpanzees, brains from ... areas of the brain that play an important role ... and creativity are immature in both chimps and humans, ...
Cached Medicine News:Health News:Parkinson's Patients May Fare Better in Neurologist's Care 2Health News:Prehistoric Water Reptile's Social Life Similar to Dolphins: Study 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Women Born After Great Depression Had More Children, Study Finds 2
... CELL-DYN 1800 is the latest 3-part differential ... since the founding of the CELL-DYN line. ... data management capabilities, the CELL-DYN 1800 meets ... CELL-DYN 1800 is smaller than its predecessors ...
... Net Point-of-Care Data Networking is hospital ... of data networking. In seconds, point ... be transferred from nursing stations throughout ... is instantly available to laboratory staff ...
... EarlyDetect® Menopause Test is a one ... menopause has occured. This test can ... follicle-stimulating hormone (FSH), which indicates whether ... simple to use and in a ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
Medicine Products: